Device
Apollo ESG
Apollo ESG is a medical device with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
unknown1
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A
Trials by Phase
N/A3 (100.0%)
Trials by Status
unknown133%
active_not_recruiting133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
completednot_applicable
Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Trial
NCT05559866
active_not_recruitingnot_applicable
ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)
NCT05578703
unknownnot_applicable
ABLATE WEIGHT 2 (Single-Stage Fundic Ablation Plus ESG for Weight Loss)
NCT05992103
Clinical Trials (3)
Showing 3 of 3 trials
NCT05559866Not Applicable
Hybrid Argon Plasma Coagulation and Endoscopic Sleeve Gastroplasty Trial
NCT05578703Not Applicable
ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)
NCT05992103Not Applicable
ABLATE WEIGHT 2 (Single-Stage Fundic Ablation Plus ESG for Weight Loss)
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3